title: Adhesion molecules and p16 expression in endocervical adenocarcinoma.
abstract: An immunohistochemical (IHC) study has been conducted on 34 cases of untreated endocervical adenocarcinomas collected among three institutions (Ospedale S. Andrea, Rome; Istituto Nazionale Tumori "Fondazione G. Pascale", Naples; and Clinica Malzoni, Avellino). The E-cadherin and alpha- and beta-catenin complex status has been investigated along with p16INK4a in all studied cases with the aim to study whether the pattern of expression of the cadherin-catenin complex could be causally related to the expression of P16INK4a protein. Results were evaluated for statistical significance by a non-parametric test (Kruskal-Wallis). Endocervical adenocarcinomas as a group were uniformly expressing p16INK4a except for two cases, and all lesions displayed downregulation of the cadherin-catenin complex, without demonstrating statistically significant differences among the different histotypes. The lack of nuclear accumulation of beta-catenin found in this group of lesions probably implies that no alteration of the beta-catenin/Wnt metabolic pathway is present in endocervical adenocarcinoma, as opposed to what is found in the literature for squamous carcinoma of the cervix. The diffuse expression of p16INK4a protein in this group of neoplasms stresses the important role of high-risk human papillomavirus infection in neoplastic causation possibly via the viral E7-mediated inactivation of pRB tumor-suppressor protein and also underlines the useful role of p16INK4a immunostaining in the diagnostic algorithm of endocervical adenocarcinomas. In consideration of these findings, investigation of downstream beta-catenin genes c-myc and cyclin D1 is sought as possibly contributive in the molecular pathogenesis of endocervical adenocarcinoma.
authors.affiliation: U.O. Citopatologia, IIa Facoltà Medicina e Chirurgia La Sapienza, Rome, Italy.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Carico
authors.forename: Franco
authors.initials: F
authors.lastname: Fulciniti
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Giovagnoli
authors.forename: Nunzia Simona
authors.initials: NS
authors.lastname: Losito
authors.forename: Gerardo
authors.initials: G
authors.lastname: Botti
authors.forename: Giulio
authors.initials: G
authors.lastname: Benincasa
authors.forename: Maria Giuseppina
authors.initials: MG
authors.lastname: Farnetano
authors.forename: Aldo
authors.initials: A
authors.lastname: Vecchione
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry*; D000328:Adult; D000368:Aged; D015820:Cadherins / Q000032:analysis*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D002583:Uterine Cervical Neoplasms / Q000737:chemistry*; D051178:alpha Catenin / Q000032:analysis*; D051176:beta Catenin / Q000032:analysis*
chemical_list: D015820:Cadherins; D019941:Cyclin-Dependent Kinase Inhibitor p16; D051178:alpha Catenin; D051176:beta Catenin
references.citation: Gynecol Oncol. 2000 Aug;78(2):97-105
references.pmid: 10926787
references.citation: Am J Surg Pathol. 2003 Feb;27(2):187-93
references.pmid: 12548164
references.citation: Virchows Arch A Pathol Anat Histopathol. 1992;421(2):149-56
references.pmid: 1514246
references.citation: Int J Cancer. 1994 Aug 1;58(3):393-9
references.pmid: 7519585
references.citation: Int Arch Med. 2008 Jul 07;1(1):10
references.pmid: 18606007
references.citation: Science. 2002 May 17;296(5571):1308-13
references.pmid: 11964443
references.citation: Anticancer Res. 2004 Nov-Dec;24(6):3843-50
references.pmid: 15736420
references.citation: J Pathol. 2003 Apr;199(4):471-8
references.pmid: 12635138
references.citation: J Pathol. 1995 Jun;176(2):151-9
references.pmid: 7636625
references.citation: Cancer Res. 1992 Apr 1;52(7):1981-7
references.pmid: 1551127
references.citation: Virchows Arch. 2001 Dec;439(6):725-51
references.pmid: 11787845
references.citation: Cancer Lett. 1996 May 15;103(1):11-7
references.pmid: 8616803
references.citation: Cancer. 2002 Feb 25;96(1):5-13
references.pmid: 11836697
references.citation: Oncol Rep. 2002 Sep-Oct;9(5):915-28
references.pmid: 12168049
references.citation: J Pathol. 1998 Jul;185(3):267-72
references.pmid: 9771480
references.citation: World J Surg Oncol. 2005 Jun 21;3:38
references.pmid: 15969753
references.citation: Curr Opin Cell Biol. 1993 Oct;5(5):806-11
references.pmid: 8240824
references.citation: Br J Cancer. 1995 Jan;71(1):166-72
references.pmid: 7819034
references.citation: J Cell Biol. 1991 Apr;113(1):173-85
references.pmid: 2007622
references.citation: Am J Clin Pathol. 1996 Apr;105(4):394-402
references.pmid: 8604681
references.citation: Cancer. 1996 Apr 15;77(8 Suppl):1605-13
references.pmid: 8608551
references.citation: Gynecol Oncol. 2001 Feb;80(2):156-61
references.pmid: 11161853
references.citation: Lancet Oncol. 2008 Oct;9(10):937-45
references.pmid: 18783988
references.citation: J Cell Biol. 1994 Jun;125(6):1327-40
references.pmid: 8207061
references.citation: Mol Carcinog. 1999 Jul;25(3):207-18
references.pmid: 10411147
references.citation: Histopathology. 2004 Aug;45(2):200-2
references.pmid: 15279644
references.citation: Melanoma Res. 1996 Apr;6(2):127-31
references.pmid: 8791270
references.citation: Infect Agent Cancer. 2007 Sep 06;2:16
references.pmid: 17822553
references.citation: Int J Pancreatol. 1996 Feb;19(1):25-30
references.pmid: 8656024
references.citation: Am J Pathol. 1996 May;148(5):1375-80
references.pmid: 8623909
references.citation: Int J Mol Med. 2001 Oct;8(4):353-8
references.pmid: 11562771
references.citation: J Cell Sci. 1993 Mar;104 ( Pt 3):751-62
references.pmid: 8267793